Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360077 | 0.81 | — | — | |
| SCHEMBL13801180 | 0.77 | SLC1A2 (0.35) | — | |
| SCHEMBL10150512 | 0.73 | — | — | |
| SCHEMBL14793429 | 0.73 | — | — | |
| SCHEMBL3167547 | 0.71 | CHRM2 (0.36) | CYP3A4TSHRCYP2C19 | |
| SCHEMBL13801179 | 0.71 | CHRM2 (0.36) | CYP3A4TSHRCYP2C19 | |
| SCHEMBL20328942 | 0.68 | — | — | |
| SCHEMBL3537331 | 0.65 | — | — | |
| SCHEMBL83478 | 0.65 | — | — | |
| SCHEMBL21995884 | 0.65 | SLC6A3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244639-A4 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6495561-B2 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1244639-A1 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020055519-A1 | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists | MERCK SHARP & DOHME CORP. | 2002-05-09 | — | — | US | disclosed |
| US-6380205-B1 | QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-03-14 | — | — | US | disclosed |
| US-6291499-B1 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001032634-A1 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055519-A1 | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | CYP3A4 3323/4885TSHR 4120/4885CYP2C19 4060/4885 |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | CYP3A4 2988/4885TSHR 4548/4885CYP2C19 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.